Roland Buelow

USPTO Granted Patents = 34 (Patent Applications = 6)

CIPO Patents = 4 (Patent Applications = 4)

EPO Patents = 5 (Patent Applications = 5)

Average Co-Inventor Count = 1.8

ph-index = 10

Forward Citations = 295(Granted Patents)

Location History:

Mountain View, CA (US) (2006)
Palo Alto, CA (US) (1995 - 2024)

Company Filing History:

13 out of 34

Sangstat Medical Corporation

patents

9 out of 9

Therapeutic Human Polyclonals Inc.

Leland Stanford Junior University

patents

5. 1 out of 1

Sangstate Medical Corporation

patent

6. 1 out of 15,488

University of California

patents

7. 1 out of 2

Open Monoclonal Technology, Inc.

patents

8. 1 out of 1

Omniab Operations, Inc.

patent

9. 1 out of 480

Roche Diagnostics Gmbh

11. 2 out of 832,891

Other

patents

where one patent can have more than one assignee

Years Active: 1995-2024

Loading Chart...

34 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12016313 - Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci (2024-06-25),

2. 11230697 - Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals (2022-01-25),

3. 10385132 - Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same (2019-08-20),

4. 10370641 - Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals (2019-08-06),

5. RE47131 - Humanized immunoglobulin loci (2018-11-19),

6. 10072069 - Humanized monoclonal antibodies from a transgenic rat (2018-09-11),

7. 9476027 - Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals (2016-10-25),

8. 9475859 - Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same (2016-10-25),

9. 9388233 - Rat having a disrupted immunoglobulin gene (2016-07-12),

10. 8907157 - Methods for producing transgenic rodents having recombinant immunoglobulin loci (2014-12-09),

11. 8703485 - Germ cells having inactivated endogenous immunoglobulin genes, and transgenic animals derived therefrom (2014-04-22),

12. 8652842 - Humanized immunoglobulin loci (2014-02-18),

13. 8410333 - Humanized immunoglobulin loci (2013-04-02),

14. 8354568 - Suppression of B-cell apoptosis in transgenic animals expressing humanized immunoglobulin (2013-01-15),

15. 7919672 - Suppression of B-cell apoptosis in transgenic animals expressing humanized immunoglobulin (2011-04-05),

Title: The Innovative Contributions of Roland Buelow in Antibody Development

Introduction: Roland Buelow, based in Palo Alto, California, is an accomplished inventor in the field of biotechnology, particularly renowned for his work in immunoglobulin production. With an impressive portfolio of 34 patents, Buelow has significantly advanced the understanding and development of human antibodies using transgenic technology.

Latest Patents: Among his notable inventions are key patents that focus on the production of human antibodies from transgenic rodents. One such invention is titled "Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci". This groundbreaking invention concerns transgenic animals engineered for optimal production of functional immunoglobulins featuring human idiotypes. Another important patent is "Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals", which details the creation of transgenic animals containing humanized immunoglobulin loci alongside transgenes encoding humanized Igα and Igβ sequences. These advancements enable the production of a diversified humanized antibody repertoire while suppressing the endogenous production of traditional immunoglobulins, thereby facilitating normal B-cell development and affinity maturation.

Career Highlights: Throughout his career, Roland Buelow has made significant contributions to biotechnology while working with reputable companies such as Sangstat Medical Corporation and Therapeutic Human Polyclonals Inc. His efforts have not only generated a multitude of patents but have also placed him at the forefront of antibody research.

Collaborations: Buelow has collaborated with prominent figures in the field, including Josef Platzer and Wim van Schooten. These partnerships have helped to amplify the impact of his research and innovations on the wider scientific community.

Conclusion: Roland Buelow’s contributions to the field of immunology through his innovative patented technologies demonstrate his commitment to advancing antibody development. His work has paved the way for new therapeutic methodologies, underscoring the critical role that inventors like him play in driving innovation in biotechnology.

This text is generated by artificial intelligence and may not be accurate.